When a company provides a "business strategy update" these days, the news usually includes a cutback of some kind, and Orchid BioSciences Inc. proved no exception, saying it is phasing out its single nucleotide polymorphism genotyping instruments and the related consumables in its life sciences unit. (BioWorld Today)